ARLZ - Aralez Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.3149
+0.0639 (+25.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2510
Open0.2520
Bid0.3100 x 500
Ask0.3174 x 4700
Day's Range0.2400 - 0.3278
52 Week Range0.2100 - 2.9800
Volume3,615,250
Avg. Volume1,602,000
Market Cap21.978M
Beta1.07
PE Ratio (TTM)N/A
EPS (TTM)-1.7610
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-12-31
1y Target Est3.00
Trade prices are not sourced from all markets
  • Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
    CNW Group23 days ago

    Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement

    MISSISSAUGA, Ontario, June 29, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ - News) (TSX:ARZ.TO - News) ("Aralez" or the "Company") today announced that, in connection with its review of strategic alternatives, it entered into an Amendment (the "Amendment") to that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, as amended on October 3, 2016 (the "Facility Agreement"), by and between the Company and Deerfield Partners, L.P. ("Deerfield") and certain affiliates of each party. Pursuant to the terms of the Amendment, interest due and payable on July 1, 2018 with respect to the loans under the Facility Agreement will be paid in kind, added to the outstanding principal amount of such loans and bear interest at the applicable interest rate of such loans.  The amount of interest paid in kind and the interest thereon is due and payable without premium or penalty on August 15, 2018 or such earlier date as loans maybe become due and payable.

  • Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
    CNW Group23 days ago

    Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders

    MISSISSAUGA, Ontario , June 29, 2018 /CNW/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon ...

  • ACCESSWIRE23 days ago

    Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.

  • Interested In Aralez Pharmaceuticals Inc (TSE:ARZ)? Here’s How It Performed Recently
    Simply Wall St.2 months ago

    Interested In Aralez Pharmaceuticals Inc (TSE:ARZ)? Here’s How It Performed Recently

    Investors with a long-term horizong may find it valuable to assess Aralez Pharmaceuticals Inc’s (TSX:ARZ) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Amedica Corporation and Aralez Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 9, 2018 / Aralez Pharmaceutical shares sunk on Tuesday after reporting first quarter results, despite a third consecutive quarter of positive adjusted EBITDA. Shares of Amedica had a better day yesterday exploding to a close of over 180% after providing Wall Street with some updates on its clinical study activities. The innovative biomaterial company saw its shares explode after providing an update on its clinical study activities including a Single Center Retrospective Comparative Study and a Multi-Center Retrospective Study.

  • Aralez Announces First Quarter 2018 Financial Results
    PR Newswire2 months ago

    Aralez Announces First Quarter 2018 Financial Results

    -1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez ...

  • Aralez Announces First Quarter 2018 Financial Results
    CNW Group2 months ago

    Aralez Announces First Quarter 2018 Financial Results

    -1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /CNW/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " ...

  • Aralez Announces New Strategic Direction
    PR Newswire2 months ago

    Aralez Announces New Strategic Direction

    MISSISSAUGA, Ontario, May 8, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that, based on its continuing exploration and evaluation of numerous opportunities to streamline the business, reduce costs, and improve its capital structure and liquidity, it has determined that a new strategic direction is in the best interests of the Company and its stakeholders. This strategic direction will involve (i) a focus on the Company's strong Canadian business, supported by Toprol-XL and its authorized generic (the "Toprol-XL Franchise") as well as Vimovo royalties, and (ii) the discontinuation of the remaining U.S. commercial business.

  • Aralez Announces New Strategic Direction
    CNW Group2 months ago

    Aralez Announces New Strategic Direction

    MISSISSAUGA, Ontario, May 8, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ - News) (TSX:ARZ.TO - News) ("Aralez" or the "Company") today announced that, based on its continuing exploration and evaluation of numerous opportunities to streamline the business, reduce costs, and improve its capital structure and liquidity, it has determined that a new strategic direction is in the best interests of the Company and its stakeholders. This strategic direction will involve (i) a focus on the Company's strong Canadian business, supported by Toprol-XL and its authorized generic (the "Toprol-XL Franchise") as well as Vimovo royalties, and (ii) the discontinuation of the remaining U.S. commercial business.

  • CNW Group3 months ago

    Aralez To Announce First Quarter 2018 Results On May 8, 2018

    -Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET - MISSISSAUGA, Ontario , April 27, 2018 /CNW/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that ...

  • PR Newswire3 months ago

    Aralez To Announce First Quarter 2018 Results On May 8, 2018

    -Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET - MISSISSAUGA, Ontario , April 27, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced ...

  • Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
    CNW Group4 months ago

    Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results

    -4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year ...

  • Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
    PR Newswire4 months ago

    Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results

    -4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year ...

  • ACCESSWIRE4 months ago

    Aralez Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Aralez Pharmaceuticals Inc. (NASDAQ: ARZ ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...

  • Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
    CNW Group5 months ago

    Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018

    -Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET - MISSISSAUGA, Ontario , March 6, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that ...

  • Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
    PR Newswire5 months ago

    Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018

    -Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET - MISSISSAUGA, Ontario , March 6, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced ...

  • Aralez to Present at the 2018 BIO CEO and Investor Conference
    CNW Group6 months ago

    Aralez to Present at the 2018 BIO CEO and Investor Conference

    MISSISSAUGA, Ontario , Jan. 30, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate ...

  • Aralez to Present at the 2018 BIO CEO and Investor Conference
    PR Newswire6 months ago

    Aralez to Present at the 2018 BIO CEO and Investor Conference

    MISSISSAUGA, Ontario , Jan. 30, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate ...

  • PR Newswire8 months ago

    Aralez Announces Departure of Chief Financial Officer

    MISSISSAUGA, Ontario, Nov. 30, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations.

  • CNW Group8 months ago

    Aralez Announces Departure of Chief Financial Officer

    MISSISSAUGA, Ontario, Nov. 30, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ - News) (TSX:ARZ.TO - News) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Sage Therapeutics stole the show on Thursday, with gains of over 50% at the close. The company presented positive data with analysts responding ...

  • Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
    CNW Group8 months ago

    Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter

      -3Q 2017 Net Revenues of $24.3 Million ; Year-to-Date 2017 Net Revenues of $77.9 Million -   -Implements Fiscal Improvements designed to Deliver Profitability, Support Growth & Extend Cash Runway- -Provides ...